Akebia Therapeutics Establishes Rare Kidney Disease Pipeline with Two Novel Therapeutic Candidates
核心洞察
Akebia Therapeutics acquired AKB-097 (搜索), a tissue-targeted complement inhibitor from Q32 Bio for $7 million upfront, designed to address multiple rare kidney diseases without systemic complement inhibition.
The company initiated a Phase 2 trial of praliciguat, an oral sGC (搜索) stimulator, in focal segmental glomerulosclerosis (搜索) (FSGS (搜索)), targeting up to 60 patients with primary endpoint of proteinuria reduction.
Both therapeutic programs are planned to begin patient enrollment in 2026, with AKB-097 (搜索) Phase 2 basket trial data expected in 2027.
Akebia Therapeutics announced the establishment of its rare kidney disease development pipeline, centered on two innovative therapeutic candidates targeting complement-mediated kidney diseases and focal segmental glomerulosclerosis (搜索) (FSGS (搜索)). The Cambridge-based biopharmaceutical company acquired AKB-097 (搜索), a next-generation complement inhibitor, from Q32 Bio and advanced praliciguat into Phase 2 clinical testing for FSGS.
Strategic Acquisition of Novel Complement Inhibitor
Akebia acquired global rights to AKB-097 (搜索), a tissue-targeted C3d (搜索)-Factor H (搜索) fusion protein complement inhibitor, through an asset purchase agreement with Q32 Bio signed on November 28, 2025. The transaction included a $7.0 million upfront payment, with an additional $3.0 million due at the six-month anniversary, plus development milestones, regulatory milestones, commercial milestones, and tiered royalties on net sales.
AKB-097 (搜索) represents a differentiated approach to complement inhibition, designed as a humanized anti-C3d (搜索) monoclonal antibody fusion protein that targets sites of complement activation in tissues. Unlike systemic complement inhibitors, AKB-097 is not expected to result in systemic complement inhibition, potentially addressing limitations of current approaches including infection risk and the need for high drug doses and frequent administration.
In preclinical studies conducted by Q32 Bio, AKB-097 (搜索) demonstrated distribution to affected tissues and organs with durable tissue pharmacokinetic and pharmacodynamic properties. The compound showed good tolerability and minimal anti-drug antibodies in a completed Phase 1 clinical trial in healthy volunteers.
Complement System and Therapeutic Rationale
The body's complement system (搜索) comprises a series of proteins working together as part of the immune system. When dysregulated, this system can result in numerous inflammatory and autoimmune conditions, including multiple kidney diseases. Complement inhibitors work by binding to and preventing activation of specific complement proteins, halting the cascade of inflammatory responses and reducing cellular destruction.
Akebia believes AKB-097 (搜索) has applicability across a wide range of complement-mediated rare kidney diseases (搜索). The company plans to initiate an open-label Phase 2 basket study in the second half of 2026, with initial data generation expected in 2027.
Praliciguat Development in FSGS
Separately, Akebia recently initiated a Phase 2 clinical trial evaluating praliciguat in FSGS (搜索) after filing an Investigational New Drug Application with the FDA. Praliciguat is an oral soluble guanylate cyclase (搜索) (sGC (搜索)) stimulator licensed from Cyclerion Therapeutics in June 2021.
The Phase 2 trial is expected to enroll up to 60 patients at U.S. sites, with the primary efficacy endpoint being change in urine protein-to-creatinine ratio between baseline and Week 24. The company also plans to assess praliciguat's use in other rare podocytopathies.
Previous clinical experience with praliciguat showed no significant safety issues in Phase 1 studies in healthy volunteers and Phase 2 studies in heart failure and diabetic kidney disease. Adverse events were infrequent and consistent with the compound's known blood pressure lowering effect.
Addressing Unmet Medical Need in FSGS
FSGS (搜索) is a chronic disease characterized by scarring in some parts of the kidney's filtering units known as glomeruli. Left untreated, FSGS can cause various symptoms including high cholesterol, high blood pressure, and kidney failure. The disease is heterogeneous with a wide range of causes and symptoms among those affected.
FSGS (搜索) has been diagnosed in approximately 40,000 people in the U.S. No treatments specifically indicated for FSGS are currently available on the market, with most patients treated using antihypertensives and non-specific immunosuppressive therapies.
Corporate Strategy and Leadership Perspective
"Our commitment to patients with kidney disease is supported by two pillars of our corporate strategy: first, to drive Vafseo to become standard of care in anemia due to CKD (搜索) in dialysis, and second, to build and progress our kidney disease pipeline," said John P. Butler, Chief Executive Officer of Akebia.
Butler emphasized the company's dual focus: "While our commercial and medical teams continue to build on the momentum of our Vafseo launch, we are excited to take an important step forward as a company with the establishment of our rare kidney disease development pipeline. We believe our differentiated complement inhibitor program can play a key role in addressing numerous rare kidney diseases, as can praliciguat, which we intend to initially study in FSGS (搜索)."
The company expects to begin enrolling patients in Phase 2 trials with each product candidate in 2026 and anticipates generating clinical data from the AKB-097 (搜索) Phase 2 basket trial beginning in 2027.